Delving into the Latest Updates on Tulobuterol Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Tulobuterol hydrochloride (JP17)

+ [5]

Target

β2-adrenergic receptor

Mechanism

β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists)

Therapeutic Areas

Respiratory Diseases

Active Indication

Pulmonary EmphysemaAirway Obstruction

Inactive Indication-

Originator Organization

Nipro ES Pharma KK

Active Organization

Nipro ES Pharma KK

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (01 May 1981),

Airway Obstruction

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC12H18ClNO

InChIKeyYREYLAVBNPACJM-UHFFFAOYSA-N

CAS Registry41570-61-0

View All Structures (2)

Tonsillectomy is a common pediatric procedure for the treatment of sleep-disordered breathing and chronic tonsillitis. Up to half of children having this procedure experience a perioperative respiratory adverse event.
We tried to determine whether tulobuterol patch (transdermal bronchodilator) premedication decreases the risk of perioperative respiratory adverse events in children undergoing anesthesia for tonsillectomy.

Start Date20 Dec 2019

Sponsor / Collaborator

Seoul National University Hospital

[+3]

100 Clinical Results associated with Tulobuterol Hydrochloride

Login to view more data

100 Translational Medicine associated with Tulobuterol Hydrochloride

Login to view more data

100 Patents (Medical) associated with Tulobuterol Hydrochloride

Login to view more data

9

Literatures (Medical) associated with Tulobuterol Hydrochloride

01 Dec 2008·Avian DiseasesQ4 · AGRICULTURAL & FORESTRY SCIENCE

Isolation of 4/91 Type of Infectious Bronchitis Virus as a New Variant in Japan and Efficacy of Vaccination Against 4/91 Type Field Isolate

Q4 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Shoko Suzuki ; Makiko Harada ; Yorifumi Kuroda ; Chieko Tanimura ; Yohko Shimazaki ; Shigeyuki Nakamura ; Takashi Horiuchi ; Kazuhiro Yagyu ; Yoshihisa Seki

Among field isolates of infectious bronchitis virus (IBV) from recent outbreaks, some isolates that were classified into the 4/91 genotype, by analysis of the S1 gene, have been confirmed to be a new variant in Japan. To elucidate the characteristics of these isolates, pathogenicity in chicks and the efficacy of vaccines against this new variant were examined. Severe respiratory symptoms were observed in 4-day-old specific pathogen free chicks inoculated with a 4/91 genotype isolate, either JP/Wakayama/2003 or JP/ Iwate/2005; body weights 3 wk after inoculation were significantly lower than those of chicks inoculated with a 4/91 vaccine strain. These 4/91 isolates were neutralized with serum from birds immunized with 4/91 vaccine. In a challenge-protection test, five groups of chicks were immunized with C78, TM-86w, H120, Kita-1, or 4/91 vaccines and then challenged with JP/Iwate/2005 4 wk after vaccination. A protective effect in the 4/91 and TM-86w vaccine groups was indicated by evaluation of the ciliostasis score of the trachea, the respiratory symptom score, and virus isolation from trachea swab samples after challenge. The results of this study suggested that the 4/91 type of IBV, which is virulent to chicks when compared to vaccine strains, has emerged as a new variant in Japan, and vaccines containing the 4/91 strain or the TM-86w strain could be effective for this variant.

01 Oct 2001·Nihon rinsho. Japanese journal of clinical medicine

[Japanese guideline for the diagnosis and management of bronchial asthma (1998)--its results and reversion].

Review

Author: Numao, T ; Fukuda, T

Japanese guideline for the diagnosis and management of bronchial asthma was initially reported in 1998 and revised in 2000. This guideline was based on two former guidelines which were made by Japanese Allergology Society in 1993 and NIH.NHLBI in 1995 (GINA). New version of this guideline in 2000 pointed that the efficacy and adverse reaction of leukotriene receptor antagonists, the effectiveness of new inhaled corticosteroid (fluticasone propionate), and transdermal administration of beta-2 stimulant (tulobuterol hydrochloride). The precise evaluation of this guideline in terms of propriety, reliability, applicability and so on was not performed.

01 Feb 1995·Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & ImmunologyQ2 · MEDICINE

Pharmacokinetics and pharmacodynamics of the tulobuterol patch, HN-078, in childhood asthma.

Q2 · MEDICINE

Article

Author: Miura, K ; Akimoto, K ; Tsubaki, T ; Kabayama, H ; Yagi, K ; Uchiyama, H ; Ebisawa, M ; Ishizu, H ; Iikura, Y ; Sakaguchi, N

BACKGROUNDRecently, a novel percutaneous adhesive tulobuterol preparation, HN-078, has been developed and tests using healthy adult subjects have indicated it to be effective for controlling exacerbations early in the morning if applied at bedtime. In children, percutaneous application is very important to eliminate side effects, including abdominal pain and appetite loss.OBJECTIVEWe report the pharmacokinetics and pharmacodynamics of tulobuterol patch, HN-078, in the treatment of childhood asthma.METHODSSingle applications of HN-078 were applied transdermally in six children with asthma who had been admitted to a hospital. Subjects weighing less than 30 kg received 1 mg of tulobuterol while subjects weighing 30 kg or above received 2 mg on the chest for 24 hours. Serum tulobuterol levels and peak expiratory flow rate were determined before and after each application.RESULTSCmax of tulobuterol was determined to be 1.33 +/- 0.21 ng/mL, Tmax was 14.0 +/- 2.0 hours, and AUCO-t was 27.1 +/- 4.2 ng.hr/mL. These pharmacokinetic parameters per body surface area of children were nearly equivalent to those of adults obtained in other studies. Peak expiratory flow rate values obtained after application of HN-078 significantly increased in comparison to those obtained before application. No significant changes were observed in pulse rate or blood pressure, and no side effects were found with regard to the subjective symptoms and skin conditions.CONCLUSIONSThese results suggest that the patch formulation of tulobuterol, HN-078, will be very useful for the treatment of pediatric asthma. It is especially significant that no side effects were observed.

100 Deals associated with Tulobuterol Hydrochloride

Login to view more data